Top Story - Ranbaxy Laboratories new malaria drug proves effective and safe in mid-stage trial

26 Aug 2010 Evaluate

An experimental malaria drug developed by Ranbaxy Laboratories Ltd. was effective and safe in a mid-stage clinical trial, according to a study that suggests the treatment may offer an alternative to current medicines. Among 230 people with the deadliest form of malaria in Thailand, India and Tanzania, Ranbaxy’s arterolane cleared the disease in as many as 72 percent of patients within 28 days.

Malaria strikes about 250 million people each year and kills more than 880,000, mostly children under 5 in Africa, according to the World Health Organization. It’s the world’s third-deadliest infectious disease, with only AIDS, which results in about 2 million deaths each year, and tuberculosis, which kills 1.6 million people annually, according to WHO.

A study published in the New England Journal of Medicine last year showed drugs derived from artemisinin took almost twice as long to clear the parasites that cause the disease in patients in western Cambodia as in patients in northwestern Thailand. Ranbaxy is now studying arterolane in combination with an older drug, piperaquine, in a late-stage patient study in India, Bangladesh and Thailand.

crackcrack
Peers
Company Name CMP
Sun Pharma Inds. 1705.15
Dr. Reddys Lab 1155.80
Cipla 1481.40
Lupin 2012.05
Zydus Lifesciences 884.20
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...